Lay Synthia, Nguyen Long L, Yan Yueqi, Chan-Golston Alec M, De Santiago Angel, Sidhu Rubani, Yasaei Rama
Psychiatry, Kaweah Delta Health Care District, Visalia, California, USA
Psychiatry, Kaweah Delta Health Care District, Visalia, California, USA.
BMJ Open. 2025 Jul 10;15(7):e092122. doi: 10.1136/bmjopen-2024-092122.
The association between smoking and patients with schizophrenia has been established through epidemiological studies on various populations. This behaviour not only increases the risk of medical comorbidities associated with smoking, but it can also interfere with treatment and ultimately worsen prognosis. This study aims to determine if nicotine use affects the cumulative number of psychiatric hospitalisations in patients with schizophrenia.
This is a retrospective cohort study using 2018-2023 electronic medical record data.
Data was collected at an inpatient psychiatric hospital in Central California.
There were a total of 825 patients with diagnoses of schizophrenia or schizoaffective disorder who were admitted to the mental health hospital between 2018 and 2023.
The primary outcome of interest was the number of psychiatric hospitalisations observed among the patients who were smokers versus those who were non-smokers. Our secondary objective was to determine the prevalence of certain medical comorbidities between these two groups.
60.7% of patients had a lifetime smoking history. Accounting for matching, patients who smoked had significantly (p<0.01) more hospitalisations (mean hospitalisations=2.55, SD=2.81) than patients who never smoked (mean hospitalisations=1.64, SD=1.64), even after controlling for covariates. The smoking group also had a higher prevalence of medical comorbidities, but after matching, no difference was found between the groups.
Patients with schizophrenia and a lifetime smoking history had significantly more hospitalisations compared with patients with schizophrenia who were non-smokers. This can inform disease course in vulnerable populations with a greater propensity to self-medicate with substances. However, further research should be conducted to investigate other factors that can affect this relationship.
通过对不同人群的流行病学研究,吸烟与精神分裂症患者之间的关联已得到证实。这种行为不仅会增加与吸烟相关的合并症风险,还会干扰治疗并最终恶化预后。本研究旨在确定使用尼古丁是否会影响精神分裂症患者的累计精神病住院次数。
这是一项使用2018 - 2023年电子病历数据的回顾性队列研究。
数据收集于加利福尼亚州中部的一家住院精神病医院。
2018年至2023年间,共有825名被诊断为精神分裂症或分裂情感性障碍的患者入住该精神卫生医院。
主要关注的结局是吸烟者与非吸烟者之间观察到的精神病住院次数。我们的次要目标是确定这两组之间某些合并症的患病率。
60.7%的患者有终生吸烟史。在进行匹配后,即使在控制协变量后,吸烟患者的住院次数(平均住院次数 = 2.55,标准差 = 2.81)仍显著多于从不吸烟的患者(平均住院次数 = 1.64,标准差 = 1.64)(p<0.01)。吸烟组的合并症患病率也更高,但在匹配后,两组之间未发现差异。
与非吸烟的精神分裂症患者相比,有终生吸烟史的精神分裂症患者住院次数显著更多。这可以为有更大自我用药倾向的脆弱人群的疾病进程提供参考。然而,应进行进一步研究以调查其他可能影响这种关系的因素。